TUDCA‘s neuroprotective research is best known through ALS, Parkinson‘s, and Huntington’s disease. Alzheimer’s disease is a separate question with its own evidence base, and it is one of the few neurodegenerative indications where TUDCA has actually reached a human trial, as one half of the combination drug sodium phenylbutyrate and taurursodiol (PB and TURSO). Taurursodiol is TUDCA.
That trial, PEGASUS, is the single most informative piece of evidence on this topic, and its headline result was that the clinical efficacy outcomes did not significantly differ between treatment and placebo. That deserves to lead rather than be buried under mechanism discussion. This article covers the trial, the biomarker findings that were more interesting than the clinical ones, and the preclinical work behind it. None of it is medical advice.
Key Takeaways
- PEGASUS was a phase 2a trial of PB and TURSO in Alzheimer’s disease that enrolled 95 participants [1]. Taurursodiol is TUDCA; it was tested combined with sodium phenylbutyrate, not alone.
- Clinical efficacy outcomes did not significantly differ between the treatment and placebo groups in the intent-to-treat cohort [1]. The trial missed on cognition, function, and hippocampal volume.
- In the treated group, cerebrospinal fluid biomarkers including phosphorylated tau-181, total tau, neurogranin, FABP3, and YKL-40 were reduced, while the oxidative stress marker 8-OHdG increased [1]. Between-group differences were seen for several of these.
- Baseline cognitive impairment was significantly worse in the treatment group than in placebo [1], a randomization imbalance that complicates interpretation of the clinical result.
- Preclinical work shows TUDCA reduces p53-mediated apoptosis in neuroblastoma cells carrying Alzheimer’s mutations (APPswe and APPswe/ΔE9) [2], the mechanistic basis for the human trials.
Why TUDCA Was Tested in Alzheimer’s at All
Two of the mechanisms implicated in Alzheimer’s pathophysiology, endoplasmic reticulum stress and mitochondrial dysfunction, are the two mechanisms TUDCA is best characterized as addressing [1]. Sodium phenylbutyrate targets the first and taurursodiol targets the second, which is why they were combined into a single agent rather than tested separately.
The mechanistic rationale is stronger than the usual supplement-to-disease story. TUDCA was not chosen because it is a bile acid people already take; it was chosen because the pathway it acts on is one of many implicated in the disease. That is also its limitation: ‘one of many mechanisms’ is exactly how the trial authors framed it.
The Preclinical Basis
The cleanest mechanistic study used mouse neuroblastoma cells engineered to express either wild-type amyloid precursor protein, APP with the Swedish mutation (APPswe), or double-mutated human APP and presenilin 1 (APPswe/ΔE9), all of which increase amyloid-beta production and aggregation [2].
Cell viability dropped in the mutant lines, with nuclear fragmentation and activation of caspases 2, 6, and 8 detectable. TUDCA reduced nuclear fragmentation and caspase 2 and 6 activity (though not caspase 8), and modulated p53 activity along with Bcl-2 and Bax. Overexpressing p53 was itself sufficient to induce apoptosis in these cells, and TUDCA reduced that too [2].
A 2024 review synthesizing this literature proposed that TUDCA’s potential Alzheimer’s mechanisms include reducing amyloid-beta deposition, regulating apoptotic pathways, preventing tau hyperphosphorylation and aggregation, protecting neuronal synapses, anti-inflammatory activity, and improving metabolic disorders [3]. That is a broad list, and reviews proposing mechanisms are not evidence that those mechanisms operate in patients.
PEGASUS: The Human Trial
PEGASUS was described by its authors as the first-in-indication phase 2a trial of PB and TURSO in Alzheimer’s disease, designed to gain insight into target engagement and disease biology rather than to prove efficacy [1]. It enrolled 95 participants: 51 on PB and TURSO, 44 on placebo.
The primary clinical efficacy outcome was a global statistical test combining three endpoints: cognition (Mild/Moderate Alzheimer’s Disease Composite Score), function (Functional Activities Questionnaire), and total hippocampal volume on MRI. Secondary outcomes included additional cognitive, functional, and neuropsychiatric assessments. CSF biomarkers were an exploratory outcome [1].
The result on the primary: clinical efficacy outcomes did not significantly differ between treatment groups in the intent-to-treat cohort [1]. There is no way to soften that. The drug did not demonstrate a clinical benefit.
One design detail matters for interpretation in both directions: cognitive assessments indicated significantly greater baseline cognitive impairment in the PB and TURSO group than in placebo [1]. Randomization did not produce balanced groups on the key prognostic variable. That makes a negative clinical result harder to attribute cleanly to the drug, and it is also the kind of imbalance that invites post-hoc reinterpretation. The honest position is that the trial was not able to answer the efficacy question.
The Biomarker Findings
In the subset with both baseline and week 24 CSF samples (33 treated, 34 placebo), the treated group showed reductions in core Alzheimer’s biomarkers phosphorylated tau-181 and total tau; in the synaptic and neuronal degeneration markers neurogranin and FABP3; and in the gliosis marker YKL-40. The oxidative stress marker 8-OHdG increased. CSF interleukin-15 increased within the placebo group [1]. Between-group differences were observed for the Aβ42/40 ratio, p-tau181, and total tau.
Biomarker movement without clinical benefit is a familiar and frustrating pattern in Alzheimer’s drug development. It is consistent with the drug engaging its targets. It is not evidence that engaging those targets helps patients, and the field has repeatedly seen compounds move biomarkers without changing disease trajectory. The increase in the oxidative stress marker also cuts against a simple ‘everything improved’ reading.
The ALS Context
The same combination was tested in ALS, where a phase 2 randomized trial published in 2020 reported a slower rate of functional decline than placebo [4]. That result led to regulatory approval, which was later withdrawn after a larger phase 3 trial failed to confirm the benefit.
That history is directly relevant here. A promising phase 2 signal in a neurodegenerative disease is not a reliable predictor of phase 3 success, and in this specific drug’s case it already failed to replicate once. Alzheimer’s evidence for PB and TURSO is weaker than the original ALS evidence was.
What This Evidence Can and Cannot Tell Us
What it can tell us: TUDCA, as half of a combination drug, has been given to Alzheimer’s patients in a controlled trial and produced measurable changes in CSF biomarkers of tau pathology and neurodegeneration over 24 weeks [1].
What it cannot tell us: whether TUDCA helps anyone with Alzheimer’s disease. The clinical endpoints missed [1]. It also cannot tell us anything about TUDCA taken alone, because the trial tested it combined with sodium phenylbutyrate, and there is no way to attribute any observed effect to one component.
Anyone considering TUDCA for cognitive concerns should understand they would be acting well ahead of the evidence, on a different formulation than was studied, for an indication where the one controlled human trial did not show clinical benefit. Alzheimer’s care involves diagnostic workup, treatable contributing conditions, and now approved disease-modifying options for selected patients. That belongs with a neurologist.
Frequently Asked Questions
Is taurursodiol the same thing as TUDCA?
Yes. Taurursodiol is the pharmaceutical name for tauroursodeoxycholic acid. In PEGASUS and the ALS trials it was combined with sodium phenylbutyrate, not given alone [1][4].
Did the Alzheimer’s trial work?
No, on its clinical endpoints. Cognition, function, and hippocampal volume did not significantly differ from placebo in the intent-to-treat cohort [1]. Some CSF biomarkers did move, which is a mechanism finding rather than a benefit finding.
Why did the ALS approval get withdrawn if the phase 2 was positive?
The 2020 phase 2 trial reported slower functional decline than placebo [4], but the subsequent larger phase 3 trial did not confirm it and the product was withdrawn. It is a useful reminder of how often phase 2 signals in neurodegeneration fail to replicate.
Should I take TUDCA for memory or cognitive decline?
The evidence does not support that. The preclinical work is cell-culture [2], the review-level mechanisms are proposals rather than demonstrations [3], and the one controlled human trial missed its clinical endpoints [1]. Cognitive changes warrant medical evaluation, not supplementation in place of it.
References
- Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2024).
- Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer’s disease mutant neuroblastoma cells. Journal of Neurochemistry (2006).
- Tauroursodeoxycholic acid: a bile acid that may be used for the prevention and treatment of Alzheimer’s disease. Frontiers in Neuroscience (2024).
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine (2020).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
